References
1.M. Samson, X. Puéchal, H. Devilliers C. Ribi, P. Cohen, B. Bienvenu et al., “Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors,” Autoimmunity Reviews, vol. 13, no. 9, pp. 945–953, 2014.
2.C. Comarmond, C. Pagnoux, M. Khellaf, J. Cordier, M.Hamidou, J. Viallard et al., “Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort,” Arthritis & Rheumatism, vol. 65, no. 1, pp. 270–281, 2013.
3.J. Wolf, V. Schmitt, F. Palm, A. J. Grau, and R. Bergner, “Peripheral neuropathy as initial manifestation of primary systemic vasculitides,” Journal of Neurology, vol. 260, no. 4, pp. 1061–1070, 2013.
4. Cattaneo L, Chierici E, Pavone L, Grasselli C, Manganelli P, Buzio C, et al. Peripheral neuropathy in Wegener’s granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry. 2007;78:1119–23.
5. Hattori N, Ichimura M, Nagamatsu M, Li M, Yamamoto K, Kumazawa K, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain. 1999;122(Pt 3):427–39.
6. Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, Stern M et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J 2013;43(6):60–69.